Circulating Long Non-Coding RNAs as Novel Potential Biomarkers for Osteogenic Sarcoma
by
, ,
Sutpirat Moonmuang
1
,
Parunya Chaiyawat
1,2,
Salinee Jantrapirom
3,4,
Dumnoensun Pruksakorn
1,2,5,* and
Luca Lo Piccolo
1,*
1
Center of Multidisciplinary Technology for Advanced Medicine (CMUTEAM), Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand
2
Musculoskeletal Science and Translational Research Center (MSTR), Faculty of Medicine, Chiang Mai University, Muang, Chiang Mai 50200, Thailand
3
Drosophila Center for Human Diseases and Drug Discovery (DHD), Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand
4
Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand
5
Department of Orthopedics, Faculty of Medicine, Chiang Mai University, 110 Intawaroros, Sriphoom, Muang, Chiang Mai 50200, Thailand
*
Authors to whom correspondence should be addressed.
Cancers 2021, 13(16), 4214; https://doi.org/10.3390/cancers13164214
Submission received: 26 July 2021
/
Revised: 9 August 2021
/
Accepted: 11 August 2021
/
Published: 21 August 2021
(This article belongs to the Special Issue Liquid Nucleic Acid-Based Biomarkers in Solid Tumors)
Simple Summary
Long non-coding RNAs (lncRNAs) can be detected in a liquid biopsy. We herein discussed the origin, methods of detection, measurement and potential functions of lncRNAs in blood. Furthermore, we used a systematic literature search to identify thirteen circulating lncRNAs whose expression was associated with bone tumor and we examined their impacts on clinical decision-making in the management of osteosarcoma.
Abstract
Circulating cell-free nucleic acids recently became attractive targets to develop non-invasive diagnostic tools for cancer detection. Along with DNA and mRNAs, transcripts lacking coding potential (non-coding RNAs, ncRNAs) directly involved in the process of tumor pathogenesis have been recently detected in liquid biopsies. Interestingly, circulating ncRNAs exhibit specific expression patterns associated with cancer and suggest their role as novel biomarkers. However, the potential of circulating long ncRNAs (c-lncRNAs) to be markers in osteosarcoma (OS) is still elusive. In this study we performed a systematic review to identify thirteen c-lncRNAs whose altered expression in blood associate with OS. We herein discuss the potential impact that these c-lncRNAs may have on clinical decision-making in the management of OS. Overall, we aimed to provide novel insights that can contribute to the development of future precision medicine in oncology.
